Anixa Biosciences (NASDAQ:ANIX) CEO Amit Kumar Buys 7,000 Shares of Stock

Anixa Biosciences Inc (NASDAQ:ANIX) CEO Amit Kumar acquired 7,000 shares of the firm’s stock in a transaction on Thursday, September 24th. The stock was purchased at an average cost of $2.78 per share, for a total transaction of $19,460.00. Following the completion of the acquisition, the chief executive officer owned 672,000 shares in the company, valued at approximately $1,868,160. This represents a 1.05% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Amit Kumar also recently made the following trade(s):

• On Thursday, September 10th, Amit Kumar acquired 3,000 shares of Anixa Biosciences stock. The shares were purchased at an average price of $2.75 per share, for a total transaction of $8,250.00.
• On Thursday, September 10th, Amit Kumar bought 5,000 shares of Anixa Biosciences stock. The shares were purchased at an average cost of $2.76 per share, with a total value of $13,800.00.
• On Friday, July 31st, Amit Kumar bought 5,000 shares of Anixa Biosciences stock. The stock was acquired at an average cost of $3.47 per share, with a total value of $17,350.00.
• On Friday, July 24th, Amit Kumar purchased 3,000 shares of Anixa Biosciences stock. The stock was acquired at an average price of $3.73 per share, for a total transaction of $11,190.00.
• On Monday, July 20th, Amit Kumar purchased 5,000 shares of Anixa Biosciences stock. The stock was acquired at an average price of $3.46 per share, for a total transaction of $17,300.00.
• On Monday, July 27th, Amit Kumar purchased 3,188 shares of Anixa Biosciences stock. The shares were acquired at an average cost of $3.37 per share, for a total transaction of $10,743.56.
• On Monday, July 27th, Amit Kumar acquired 5,000 shares of Anixa Biosciences stock. The stock was acquired at an average cost of $3.44 per share, with a total value of $17,200.00.
• On Friday, July 10th, Amit Kumar bought 5,000 shares of Anixa Biosciences stock. The shares were acquired at an average cost of $3.04 per share, for a total transaction of $15,200.00.

Anixa Biosciences Trading Up 0.4%

Shares of ANIX stock opened at $2.79 on Tuesday. The stock has a market cap of $96.98 million, a P/E ratio of -8.72 and a beta of 0.51. The stock has a 50 day simple moving average of $3.23 and a 200 day simple moving average of $2.97. Anixa Biosciences Inc has a 1 year low of $2.32 and a 1 year high of $5.46.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings data on Wednesday, September 9th. The company reported ($0.08) EPS for the quarter, hitting analysts’ consensus estimates of ($0.08). Analysts forecast that Anixa Biosciences Inc will post -0.31 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ANIX. Citigroup reiterated a “buy” rating on shares of Anixa Biosciences in a research report on Friday, June 12th. Zacks Research downgraded shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Wall Street Zen upgraded Anixa Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, June 20th. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 target price on shares of Anixa Biosciences in a report on Tuesday, June 30th. Finally, Weiss Ratings upgraded Anixa Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 17th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $8.00.

Institutional Trading of Anixa Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Integrated Wealth Concepts LLC bought a new position in shares of Anixa Biosciences in the 2nd quarter valued at $30,000. Corient Private Wealth LP grew its position in Anixa Biosciences by 87.0% during the 2nd quarter. Corient Private Wealth LP now owns 37,400 shares of the company’s stock worth $105,000 after acquiring an additional 17,400 shares during the last quarter. AXQ Capital LP bought a new stake in Anixa Biosciences during the 2nd quarter worth $41,000. Canada Pension Plan Investment Board acquired a new position in Anixa Biosciences in the 2nd quarter worth about $38,000. Finally, Sanctuary Advisors LLC acquired a new position in Anixa Biosciences in the 2nd quarter worth about $29,000. Institutional investors own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and infectious diseases. The company’s research programs are designed to use the immune system to prevent or treat serious illnesses.

Anixa’s cancer programs include vaccine approaches for ovarian cancer and triple-negative breast cancer, developed in collaboration with researchers at Cleveland Clinic. The company is also developing chimeric antigen receptor T-cell, or CAR-T, therapies intended to target cancer cells, including programs focused on ovarian cancer.

In addition to oncology, Anixa has pursued vaccine and therapeutic technologies for infectious diseases.